Target. Test. Treat: Patient-Derived Organoids Enable Smarter Evaluation of ADCs

• PDOs act as functional ADC patient avatars, preserving tumour heterogeneity and normal tissue biology to reflect clinical efficacy and on-target/off-target toxicity
• PDOs capture variability in ADC response beyond antigen expression, enabling assessment of target engagement, internalisation, payload sensitivity, and tissue penetration
• PDOs enable the development of next generation therapeutic strategies, allowing for testing of combination therapies and comparison with SoC data in patient relevant models

Speakers:

Isabella Zampeta

Scientific Business Development Manager

HUB Organoids (A Merck Company)